ArticleTuberculosis and respiratory diseases2019
Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea.
Article in Tuberculosis and respiratory diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Clinical Characteristics of Individuals with Chronic Obstructive Pulmonary Disease (COPD), Pre-COPD, Smokers with Normal Lung Function in Korea: Updated Analysis of the Korea COPD Subgroup Study Cohort.Tuberculosis and respiratory diseases · 2026Article
- Continuity of Care and Risks of Hospitalization and Mortality in COPD: A Nationwide Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Longitudinal Outcomes and Prognostic Risk of Normalized Airflow Obstruction in a Korean General Population Cohort.International journal of chronic obstructive pulmonary disease · 2026Article
- Clinical Characteristics and Frequency of Chronic Obstructive Pulmonary Disease Exacerbations in Korean Patients: Findings From the KOCOSS Cohort 2012-2021.Journal of Korean medical science · 2024Article
- Factors affecting work productivity and activity impairment among chronic obstructive pulmonary disease patients.Industrial health · 2024Article
- Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.International journal of chronic obstructive pulmonary disease · 2024Observational
- Economic Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer Between 2000 and 2015 in Saskatchewan: Study Protocol.JMIR research protocols · 2022Article
- Digital Healthcare for Airway Diseases from Personal Environmental Exposure.Yonsei medical journal · 2022Review
- Word Embedding Reveals Cyfra 21-1 as a Biomarker for Chronic Obstructive Pulmonary Disease.Journal of Korean medical science · 2021Article
- Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.Health economics review · 2021Review
- The current status of chronic obstructive pulmonary disease awareness, treatments, and plans for improvement in South Korea: a narrative review.Journal of thoracic disease · 2021Review
- Epidemiology, burden, and policy of chronic obstructive pulmonary disease in South Korea: a narrative review.Journal of thoracic disease · 2021Review
- Hospitalization increases while economic status deteriorates in late stages of chronic obstructive pulmonary disease: the Korean National Health and Nutrition Examination Survey for 2007-2015.Journal of thoracic disease · 2021Article
- Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea.Tuberculosis and respiratory diseases · 2021Article
- The Association with COPD Readmission Rate and Access to Medical Institutions in Elderly Patients.International journal of chronic obstructive pulmonary disease · 2021Article
- Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea.Risk management and healthcare policy · 2021Article
- Health Effects of Ozone on Respiratory Diseases.Tuberculosis and respiratory diseases · 2020Article
- Nationwide quality assessment of treatment for chronic obstructive pulmonary disease.Journal of thoracic disease · 2020Article
- Polyunsaturated fatty acids, lung function, and health-related quality of life in patients with chronic obstructive pulmonary disease.Yeungnam University journal of medicine · 2020Article
- Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India.PharmacoEconomics - open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundUnderstanding the burden of disease is important to establish cost-effective treatment strategies and to allocate healthcare resources appropriately. However, little reliable information is available regarding the overall economic burden imposed by chronic obstructive pulmonary disease (COPD) in Korea.
methodsThis study is a multicenter observational research on the COPD burden in Korea. Total COPD costs were comprised of three categories: direct medical, direct non-medical, and indirect costs. For direct medical costs, institutional investigation was performed at 13 medical facilities mainly based on the claims data. For direct non-medical and indirect costs, site-based surveys were administered to the COPD patients during routine visits. Total costs were estimated using the COPD population defined in the recent report.
resultsThe estimated total costs were approximately 1,245 million US dollar (1,408 billion Korean won). Direct medical costs comprised approximately 20% of the total estimated costs. Of these, formal medical costs held more than 80%. As direct non-medical costs, nursing costs made up the largest percentage (39%) of the total estimated costs. Costs for COPD-related loss of productivity formed four fifths of indirect costs, and accounted for up to 33% of the total costs.
conclusionThis study shows for the first time the direct and indirect costs of COPD in Korea. The total costs were enormous, and the costs of nursing and lost productivity comprised approximately 70% of total costs. The results provide insight for an effective allocation of healthcare resources and to inform establishment of strategies to reduce national burden of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.